107 related articles for article (PubMed ID: 24966144)
1. How much is fatigue explained by standard clinical characteristics of disease activity in patients with inflammatory arthritis? A longitudinal study.
Minnock P; McKee G; Bresnihan B; FitzGerald O; Veale DJ
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1597-603. PubMed ID: 24966144
[TBL] [Abstract][Full Text] [Related]
2. Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis.
Minnock P; Kirwan J; Bresnihan B
Rheumatology (Oxford); 2009 Dec; 48(12):1533-6. PubMed ID: 19773406
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
Gladman DD; Bombardier C; Thorne C; Haraoui B; Khraishi M; Rahman P; Bensen W; Syrotuik J; Poulin-Costello M
J Rheumatol; 2011 Jul; 38(7):1355-62. PubMed ID: 21572156
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy.
Wolfe F; Pincus T; O'Dell J
J Rheumatol; 2001 Jul; 28(7):1712-7. PubMed ID: 11469486
[TBL] [Abstract][Full Text] [Related]
5. Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.
Kristensen LE; Bliddal H; Christensen R; Karlsson JA; Gülfe A; Saxne T; Geborek P
Arthritis Care Res (Hoboken); 2014 Feb; 66(2):173-9. PubMed ID: 23982986
[TBL] [Abstract][Full Text] [Related]
6. Change in Gait Deviation Index after anti-tumour necrosis factor-α treatment in individuals with rheumatoid arthritis: a pilot study.
Broström EW; Esbjörnsson AC; von Heideken J; Larsson P; Wretenberg P; Iversen M
Scand J Rheumatol; 2013; 42(5):356-61. PubMed ID: 23581251
[TBL] [Abstract][Full Text] [Related]
7. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
[TBL] [Abstract][Full Text] [Related]
9. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
11. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
12. Comparison of physician and patient global assessments over time in patients with rheumatoid arthritis: a retrospective analysis from the RADIUS cohort.
Markenson JA; Koenig AS; Feng JY; Chaudhari S; Zack DJ; Collier D; Weaver A
J Clin Rheumatol; 2013 Sep; 19(6):317-23. PubMed ID: 23965479
[TBL] [Abstract][Full Text] [Related]
13. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
[TBL] [Abstract][Full Text] [Related]
14. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
El Miedany Y; Youssef SS; El Gaafary M
J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with fatigue in early arthritis: results from a multicenter national French cohort study.
Rat AC; Pouchot J; Fautrel B; Boumier P; Goupille P; Guillemin F
Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1061-9. PubMed ID: 22354879
[TBL] [Abstract][Full Text] [Related]
16. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
de Punder YM; Fransen J; Kievit W; Houtman PM; Visser H; van de Laar MA; van Riel PL
Rheumatology (Oxford); 2012 Sep; 51(9):1610-7. PubMed ID: 22539487
[TBL] [Abstract][Full Text] [Related]
18. Discordance and accordance between patient's and physician's assessments in rheumatoid arthritis.
Furu M; Hashimoto M; Ito H; Fujii T; Terao C; Yamakawa N; Yoshitomi H; Ogino H; Ishikawa M; Matsuda S; Mimori T
Scand J Rheumatol; 2014; 43(4):291-5. PubMed ID: 24650255
[TBL] [Abstract][Full Text] [Related]
19. The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma.
Sekhon S; Pope J; ; Baron M
J Rheumatol; 2010 Mar; 37(3):591-8. PubMed ID: 20080913
[TBL] [Abstract][Full Text] [Related]
20. Why not use OSRA? A comparison of Overall Status in Rheumatoid Arthritis (RA) with ACR core set and other indices of disease activity in RA.
Birrell FN; Hassell AB; Jones PW; Dawes PT
J Rheumatol; 1998 Sep; 25(9):1709-15. PubMed ID: 9733450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
